Resources from the same session
3575 - Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors
Presenter: Funda Meric-Bernstam
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
1831 - First in human, a phase I study of ISU104, a novel ErbB3 monoclonal antibody, in patients with advanced solid tumors
Presenter: Sung-Bae Kim
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
2878 - First-in-human, first-in-class phase I study of MTL-CEBPA, a RNA oligonucleotide targeting the myeloid cell master regulator C/EBP-_, in patients with advanced hepatocellular cancer (HCC)
Presenter: Debashis Sarker
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
5510 - Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
Presenter: Robert Charles Doebele
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
6587 - Immune activation with a novel immune switch anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in phase I/II first-in-human MATINS trial in patients with advanced solid tumors
Presenter: Petri Bono
Session: Poster Discussion – Developmental therapeutics
Resources:
Abstract
Poster Discussion – Developmental therapeutics - Invited Discussant 443PD, LBA28, 444PD and 445PD
Presenter: Christian Dittrich
Session: Poster Discussion – Developmental therapeutics
Resources:
Slides
Webcast
Poster Discussion – Developmental therapeutics - Invited Discussant 450PD, 451PD and 452PD
Presenter: Udai Banerji
Session: Poster Discussion – Developmental therapeutics
Resources:
Slides
Webcast
Poster Discussion – Developmental therapeutics - Invited Discussant LBA29, 453PD, 454PD and 455PD
Presenter: Ulrik Lassen
Session: Poster Discussion – Developmental therapeutics
Resources:
Slides
Webcast